Incyte has signed a collaboration agreement with Edison that will see the pharmaceutical company's drug discovery work used to train artificial intelligence systems. The partnership marks a growing trend of biopharma firms treating their research pipelines as data assets with value beyond the lab.
Under the deal, Edison gains access to Incyte's discovery data to develop and refine AI models, while Incyte stands to benefit from the resulting tools applied back to its research programs. The arrangement reflects how drug developers are increasingly positioning themselves as both consumers and producers of AI capability.
Incyte, known for its work in oncology and inflammation, joins a widening pool of pharma companies betting that structured biological data is among the most valuable inputs for next-generation AI in medicine. The financial terms of the agreement were not disclosed.
